SKOKIE, Ill. – April 24, 2018 – Exicure, Inc., the pioneer
in gene regulatory and immunotherapeutic drugs utilizing three-dimensional,
spherical nucleic acid (SNA™) constructs, today
announced that the Company's Chief Executive Officer, David Giljohann, Ph.D., has
been recognized by Endpoints News as
an outstanding up-and-coming biopharma professional under the age of 40.
Dr. Giljohann
was Exicure's founding scientist in 2011. He has served as Chief Executive Officer
since November 2013 and on the Company's Board of Directors since March 2014. He
completed his Ph.D. in the laboratory of Dr. Chad A. Mirkin where he developed
oligonucleotide-modified nanoparticles, including Exicure's Spherical Nucleic
Acid (SNA™) constructs.
"It is an incredible
honor to be recognized in Endpoints News'
under-40s biopharma professionals list," states Dr. Giljohann, 37. "I would
like to see a dramatic change in how quickly we can design and develop drugs
for patients in need, and this is a driving force for our team at Exicure. With
three drugs now in the clinic, we hope that the advancement of our SNA
technology can provide great promise for a broad range of chronic conditions
and orphan diseases."
Dr. Giljohann
has been recognized for his work with a Materials Research Society Gold Award,
Baxter Innovation Award, Rappaport Award for Research Excellence, NSEC
Outstanding Research Award, and as a finalist in the National Inventors Hall of
Fame Collegiate Inventors Competition. Dr. Giljohann has contributed to over 25
manuscripts and over 100 patents and applications. He received his Ph.D. in
2009 from Northwestern University.
About Exicure, Inc.
Exicure,
Inc. is a clinical stage biotechnology company developing a new class of
immunomodulatory and gene regulating drugs against validated targets. Exicure's
proprietary 3-dimensional, spherical nucleic acid (SNA™) architecture unlocks
the potential of therapeutic oligonucleotides in a wide range of cells and
tissues. Exicure's lead programs address inflammatory diseases, genetic
disorders and oncology. Exicure is based outside of Chicago, Ill. www.exicuretx.com
###
Media Contact
Karen Sharma
ksharma@macbiocom.com
781-235-3060